Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
ROSCREA, Ireland, 12th April, 2022 /PRNewswire/ – Renexxion Ireland Ltd., a private
biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need
in gastrointestinal (“GI”) disorders, announced today that it has entered into a share subscription
agreement with GEM Global Yield LLC SCS (“GEM”), a Luxembourg-based private equity group for an
investment of up to $100 Million to be made within 36 months after a public listing. In this tailored
agreement, Renexxion Ireland will control the amount and timing of any drawdowns under this facility
with no minimum subscription obligation and will issue shares of common stock. The proceeds from
this capital investment will further the company’s lead program, naronapride and advance additional
new programs.
“The benefits of a funding commitment from a strong institutional investor like GEM are certainty and
faster access to capital as a publicly listed company, critical elements for rapid growth,” said Peter
Milner M.D., FACC, Chairman and CEO.
Renexxion Ireland’s lead program is naronapride, a late-stage potential best-in-class drug candidate for
unmet GI indications in the upper and lower GI tract. In scientific studies naronapride has been
demonstrated to possess a unique combination of both serotonin 5HT4 receptor agonistic and
dopamine D2 receptor antagonistic properties, both clinically validated targets. Naronapride is designed
to be minimally absorbable, is locally active in gut lumen, and in clinical studies its side-effect profile is
indistinguishable from placebo. Four positive Phase-II studies have been completed and naronapride is
Phase-III ready in chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD).
Renexxion Ireland is currently advancing an additional research program in inflammatory bowel disease
(“IBD”).
About Renexxion:
Renexxion Ireland Ltd. is an Irish privately held biopharmaceutical company committed to delivering
new drugs to patients with GI disorders. Renexxion Ireland is currently collaborating with a leading
European GI Licensing partner to advance naronapride through the later stages of development and
commercialization in Greater Europe and certain other Australasian countries. (For information:
https://www.prnewswire.com/news-releases/renexxion-ireland-ltd-announces-a-licensing-and-
collaboration-agreement-with-dr-falk-pharma-gmbh-301392102.html ).
For information: http://www.rnexltd.ie
About the GEM Group
GEM Global Yield LLC SCS, part of the Global Emerging Markets Group, is a $3.4 billion, alternative
investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of
investment vehicles and has completed over 500 transactions in 70 countries. For information:
http://www.gemny.com
Contact:
Catherine Pearson, Chief Operating Officer, at Press@rnexltd.ie, or on +353 61 539121.
biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need
in gastrointestinal (“GI”) disorders, announced today that it has entered into a share subscription
agreement with GEM Global Yield LLC SCS (“GEM”), a Luxembourg-based private equity group for an
investment of up to $100 Million to be made within 36 months after a public listing. In this tailored
agreement, Renexxion Ireland will control the amount and timing of any drawdowns under this facility
with no minimum subscription obligation and will issue shares of common stock. The proceeds from
this capital investment will further the company’s lead program, naronapride and advance additional
new programs.
“The benefits of a funding commitment from a strong institutional investor like GEM are certainty and
faster access to capital as a publicly listed company, critical elements for rapid growth,” said Peter
Milner M.D., FACC, Chairman and CEO.
Renexxion Ireland’s lead program is naronapride, a late-stage potential best-in-class drug candidate for
unmet GI indications in the upper and lower GI tract. In scientific studies naronapride has been
demonstrated to possess a unique combination of both serotonin 5HT4 receptor agonistic and
dopamine D2 receptor antagonistic properties, both clinically validated targets. Naronapride is designed
to be minimally absorbable, is locally active in gut lumen, and in clinical studies its side-effect profile is
indistinguishable from placebo. Four positive Phase-II studies have been completed and naronapride is
Phase-III ready in chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD).
Renexxion Ireland is currently advancing an additional research program in inflammatory bowel disease
(“IBD”).
About Renexxion:
Renexxion Ireland Ltd. is an Irish privately held biopharmaceutical company committed to delivering
new drugs to patients with GI disorders. Renexxion Ireland is currently collaborating with a leading
European GI Licensing partner to advance naronapride through the later stages of development and
commercialization in Greater Europe and certain other Australasian countries. (For information:
https://www.prnewswire.com/news-releases/renexxion-ireland-ltd-announces-a-licensing-and-
collaboration-agreement-with-dr-falk-pharma-gmbh-301392102.html ).
For information: http://www.rnexltd.ie
About the GEM Group
GEM Global Yield LLC SCS, part of the Global Emerging Markets Group, is a $3.4 billion, alternative
investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of
investment vehicles and has completed over 500 transactions in 70 countries. For information:
http://www.gemny.com
Contact:
Catherine Pearson, Chief Operating Officer, at Press@rnexltd.ie, or on +353 61 539121.